GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

251 papers

Active filtersClassification:Core

Showing 133-144 of total 251 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Neuropsychiatric Effects of Glucagon-Like Peptide-1 Receptor Agonists in Schizophrenia-Spectrum Disorders: A Systematic Review.

Alsanosi ZY; Alshahrani AS; Nammazi AA; Alsunusi OA; Moafa AA; Hadi IH; Alabdali AA; Alhaqbani AW; Shahat RA; Albeladi SA; Almajdoa AA

2026PubMedDirectly related

International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update.

Mironova M; Ratziu V; Rinella ME; Bansal MB; Noureddin M; Alkhouri N; Anstee QM; Newsome PN; Schattenberg JM; Sanyal AJ; Loomba R

Jan 1, 2026Gut

2026PubMedDirectly related

Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian Randomization.

Zhang T; Luo X; Chen C; Zhang Y; Xu B; He Z; Zhou J

Jan 1, 2026The international journal of lower extremity wounds

2026PubMedDirectly related

Structural Overview of GLP-1 Analogs.

van der Velden WJC; Andresen AF; Rosenkilde MM

Jan 1, 2026Biomedical journal

2026PubMedDirectly related

Pulmonary hypertension related to sleep-disordered breathing.

LaCavera M; Asghar A; Ballard J; Bandla M; Fraidenburg DR

Jan 1, 2026Current opinion in pulmonary medicine

2026PubMedDirectly related

Obesity science, research gaps, and opportunities in the new era of obesity medicines: an Endocrine Society scientific statement.

Jastreboff AM; Ard JD; Hall KD; Kaplan LM; Krumholz HM; Van Name M; Ryan DH; Drucker DJ

Jan 1, 2026Endocrine reviews

2026PubMedDirectly related

Semaglutide and Tirzepatide for the treatment of MASH: What Works, What's Coming, and What's Missing.

Chirapongsathorn S; Tacke F

Jan 1, 2026Digestion

2026PubMedDirectly related

Trends in preoperative weight loss modalities among patients receiving body contouring surgery.

Liang J; Anderson JL; Cathey JM; Zhang J; Yi VN; Patel A

Jan 1, 2026Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery

2026PubMedDirectly related

Association of GLP-1 Receptor Agonists Versus Other Antidiabetic Medications With Cardiovascular, Renal, and Liver Outcomes in Patients With Type 2 Diabetes.

Fan Y; Peng N; Jiang L; Wei R; Lu G; Zhang S; Mu C; Xue M; Lyu B; Yao D

Jan 1, 2026Diabetes, obesity & metabolism

2026PubMedDirectly related

Digital Behavioral Infrastructure for Glucagon-Like Peptide-1 Pharmacotherapy: Viewpoint on Persistence, Tolerability, and Postcessation Durability.

Cook G

Jan 1, 2026Journal of medical Internet research

2026PubMedDirectly related

GLP-1 Receptor Agonists in Dermatology: Ethical Considerations.

Deitelzweig C; Rahim F; Stoff BK

Jan 1, 2026Clinics in dermatology

2026PubMedDirectly related

Glucagon-Like Peptide-1 Receptor Agonist Use Before and After Liver Transplant.

Manolas MI; Brown RS Jr

Jan 1, 2026Gastroenterology & hepatology